YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

Source :: PR Newswire. April 18, 2024
Publication Year :: 2024
Abstract: GAITHERSBURG, Md., April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ('YS Biopharma' or the 'Company'), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new [...]

Subjects :: Biological products industry -- Product development -- Forecasts and trends
Infection -- Forecasts and trends -- Health aspects
Hepatitis B -- Forecasts and trends -- Health aspects
Drug approval -- Health aspects -- Forecasts and trends
Hepatitis B virus -- Forecasts and trends -- Health aspects
Hepatitis B vaccine -- Product development
Market trend/market analysis
Business
News, opinion and commentary

Tools